- Vienna '18
- Athens 2019
- ESCRS Player
- On Demand
- ESCRS iLearn
- ESCRS YO's
Session Title: Glaucoma
Session Date/Time: Monday 07/10/2013 | 17:00-18:34
Paper Time: 17:40
Venue: Elicium 2 (First Floor)
First Author: : T.Neuhann GERMANY
Co Author(s): :
To evaluate safety and efficacy of the iStent® procedure reducing intraocular pressure in primary open angle - and pseudoexfoliation glaucoma. By creating a direct access to Schlemm"s canal, the iStent can reestablish physiologic outflow and reduce intraocular pressure (IOP).
AaM Augenklinik am Marienplatz Munich, Germany
The iStent is preloaded in a single-use sterile applicator to facilitate manipulation and placement into Schlemm"s canal. The iStent was implanted through the same temporal, limbal incision used for MICS phacoemulsification in 59 eyes of 43 subjects. For best possible angle visualization, iStent insertion was performed from the temporal side with the help of a gonioscopic lens under the microscope tilted towards the surgeon. The patient"s head was tilted away from the surgeon.
Preoperatively, 56 eyes required topical anti-hypotensive medication and 3 did not (presented only with typical signs of POAG). Mean preoperative IOP was 23.8 (± 7.0) mmHg. Mean IOP had reduced to 14.8 (±3.8) mmHg at 1 month postoperative, 14.8 (±4.1) mmHg at 12 months and 15.4 (± 2.1) mmHg at 24 months. Medications were reduced or eliminated in 75% of eyes. No intra- or postoperative complications typically seen with conventional glaucoma surgeries occurred after stent implantation. All eyes achieved BCVA of 20/40 or better.
The iStent is a safe and effective treatment option in patients with ocular hypertension or open-angle glaucoma. In our series it reduced IOP and the need for ocular hypotensive treatment and/or significantly reduced the number of hypotensive medications through two years postoperative. Longer-term data past 24 months will be presented.
Please wait while information is loading.